Goldman Sachs
GPCR icon

Goldman Sachs’s Structure Therapeutics GPCR Stock Holding History

Goldman Sachs’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13M Sell
242,790
-17,753
-7% -$785K ﹤0.01% 3024
2026
Q1 		$12.6M Buy
260,543
+36,211
+16% +$2.48M ﹤0.01% 2864
2025
Q4 		$15.6M Sell
224,332
-280,064
-56% -$11.4M ﹤0.01% 2626
2025
Q3 		$14.1M Buy
504,396
+284,222
+129% +$5.66M ﹤0.01% 2623
2025
Q2 		$4.57M Sell
220,174
-104,261
-32% -$2.29M ﹤0.01% 3513
2025
Q1 		$5.62M Sell
324,435
-258,430
-44% -$6.33M ﹤0.01% 3233
2024
Q4 		$15.8M Sell
582,865
-129,930
-18% -$4.61M ﹤0.01% 2355
2024
Q3 		$31.3M Buy
712,795
+30,432
+4% +$1.18M 0.01% 1656
2024
Q2 		$26.8M Buy
682,363
+233,692
+52% +$9.6M ﹤0.01% 1639
2024
Q1 		$19.2M Buy
448,671
+20,936
+5% +$883K ﹤0.01% 1871
2023
Q4 		$17.4M Buy
427,735
+356,302
+499% +$20.4M ﹤0.01% 2028
2023
Q3 		$3.6M Buy
+71,433
New +$2.3M ﹤0.01% 3289

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs's GPCR Position: Q2 2026 in Review

Goldman Sachs reduced its Structure Therapeutics (GPCR) stake by 6.8% in Q2 2026, selling an estimated $785K and leaving 242,790 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #3024.

Goldman Sachs first reported a position in GPCR in Q3 2023 and has held it in 12 quarters since. The position peaked at $31.3M in Q3 2024. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Goldman Sachs held 242,790 shares of Structure Therapeutics worth $13M as of Q2 2026.
  • Goldman Sachs sold 17,753 Structure Therapeutics shares in Q2 2026, an estimated $785K.
  • Structure Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3024 holding.
  • Goldman Sachs first reported a position in Structure Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Goldman Sachs's Structure Therapeutics position peaked at $31.3M in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.